In 2012, researchers from Stony Brook University established a new company called Theragnostic Technologies to develop a new efficient graphene-based MRI contrast agent that is safer and cheaper than current gadolinium-based agents.
Next month the company is set to unveil its product, the ManGraDex graphene-based MRI agent. The company says that this new contrast agent will greatly improve the MRI safety and efficacy of MRI - and will also expand the MRI market into unserved renal and cardiovascular patients.
Source:
Posted: May 25,2015 by Ron Mertens
